At a glance
ClinicalIndex Comparison RecordN/ACompleted· 2,032 enrolled
Drug / intervention
xinzhijundrug
Likely dose
xinzhijun 3.0gfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Open Multi-center Clinical Study on Cefotaxime Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary Tract Infection
In Brief
An observational study evaluating xinzhijun for Respiratory Tract Infections and Urinary Tract Infections. Completed, enrolled 2,032 participants.
Detailed Summary
In the proposed study, the investigators plan to evaluate the efficacy and safety of Cefotaxime sodium and sulbactam sodium for injection (2:1)for the treatment of respiratory and urinary tract acute bacterial infection under the widely used in clinical conditions.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedAug 2011
Primary CompletionApr 2015
Study CompletionDec 2016
TodayJul 2026
First PostedAug 31, 2011
Enrollment StartAug 1, 2011
Primary CompletionApr 1, 2015
Study CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 14.8 years ago
Interventions
xinzhijundrug
durg:Cefotaxime sodium and sulbactam sodium for injection(2:1) 1.5-3.0g,iv,bid or tid for 5-12 days; Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days